2020 Vaccinology Club of French Society for Immunology
January 16-17, 2020
Lille
Osivax is proud to announce that its oral presentation has been selected to be presented at the Vaccinology Club of French Society for Immunology at the Institut Pasteur in Lille on January 16-17, 2020. Florence Nicolas, Chief Development Officer and Co-founder of Osivax will be presenting the immunogenicity results from our Phase 1 clinical trial on OVX836, universal flu vaccine candidate via IM and IN routes. This meeting will cover many aspects of vaccinology with sessions devoted to advances in fundamental research, the development of new vaccine approaches and new methods for monitoring the effectiveness of vaccines, and the latest results of clinical trials. One of the main objectives of Vaccinology Club is to raise awareness on the work of young scientists and clinical trial investigators and also to create a new generation of committed people interested in vaccine development and application.
https://www.alphavisa.com/vcm/2020/index.php
Lille
Osivax is proud to announce that its oral presentation has been selected to be presented at the Vaccinology Club of French Society for Immunology at the Institut Pasteur in Lille on January 16-17, 2020. Florence Nicolas, Chief Development Officer and Co-founder of Osivax will be presenting the immunogenicity results from our Phase 1 clinical trial on OVX836, universal flu vaccine candidate via IM and IN routes. This meeting will cover many aspects of vaccinology with sessions devoted to advances in fundamental research, the development of new vaccine approaches and new methods for monitoring the effectiveness of vaccines, and the latest results of clinical trials. One of the main objectives of Vaccinology Club is to raise awareness on the work of young scientists and clinical trial investigators and also to create a new generation of committed people interested in vaccine development and application.
https://www.alphavisa.com/vcm/2020/index.php
Vaccines R&D 2019
November 18-20, 2019
Boston
Osivax is proud to announce that its oral presentation has been selected to be presented at the Fifth Edition of International Conference on Vaccines Research and Development in Boston on November 18-20, 2019. Alexandre Le Vert, Chief Executive Officer and co-founder of Osivax, will be presenting the short-term immunogenicity Phase 1 results of OVX836, universal flu vaccine candidate via IM and IN routes. This meeting covers broad range of topics like new vaccine development, cancer vaccines and immunotherapy, infectious and non-infectious diseases, influenza vaccines, .... This international Conference brings together all the eminent persons of this field to share their ideas and provides a critical review of present state of subject.
https://unitedscientificgroup.com/conferences/vaccines/
Boston
Osivax is proud to announce that its oral presentation has been selected to be presented at the Fifth Edition of International Conference on Vaccines Research and Development in Boston on November 18-20, 2019. Alexandre Le Vert, Chief Executive Officer and co-founder of Osivax, will be presenting the short-term immunogenicity Phase 1 results of OVX836, universal flu vaccine candidate via IM and IN routes. This meeting covers broad range of topics like new vaccine development, cancer vaccines and immunotherapy, infectious and non-infectious diseases, influenza vaccines, .... This international Conference brings together all the eminent persons of this field to share their ideas and provides a critical review of present state of subject.
https://unitedscientificgroup.com/conferences/vaccines/
2019 World Vaccine Congress Europe
October 29-31, 2019
Barcelona
Alexandre Le Vert, Chief Executive Officer and co-founder of Osivax, will be presenting the interim safety and immunogenicity results from the first-in-human clinical trial on OVX836, Osivax universal flu vaccine candidate at the World Vaccine Congress Europe in Barcelona on October 29-31, 2019. This World Vaccine Congress series is an international event for the research, development and strategic partnering for the global vaccine industry.
https://www.world-vaccine-congress-europe
Barcelona
Alexandre Le Vert, Chief Executive Officer and co-founder of Osivax, will be presenting the interim safety and immunogenicity results from the first-in-human clinical trial on OVX836, Osivax universal flu vaccine candidate at the World Vaccine Congress Europe in Barcelona on October 29-31, 2019. This World Vaccine Congress series is an international event for the research, development and strategic partnering for the global vaccine industry.
https://www.world-vaccine-congress-europe
OPTIONS X conference for the Control of Influenza
August 28 - September 1, 2019
Singapore
Osivax is proud to announce that two oral presentations and two posters have been selected to be presented at the 10th edition of the Options X conference for the Control of Influenza conference in Singapore. This conference is ISIRV's (International Society for Influenza and other Respiratory Virus Diseases) premier event and remains the largest international conference exclusively dedicated to Influenza prevention, control and treatment. Alexandre Le Vert, Chief Executive Officer and co-founder of Osivax, will present the interim safety and immunogenicity results from the first-in-human clinical trial on OVX836, Osivax universal flu vaccine candidate. Delphine Guyon-Gellin, Chief Business Development Officer, will co-present with Nicolas Noulin from hVIVO some analyses on the impact of pre-existing NP-specific T-cell immunity on symptom reduction in human challenge model. Two posters will also be presented on OVX836 preclinical results showing that OVX836 protect ferrets in flu challenge study and that OVX836 protection is mediated by CD8 T-cells as demonstrated in mice passive transfer studies.
https://2019.isirv.org/
Singapore
Osivax is proud to announce that two oral presentations and two posters have been selected to be presented at the 10th edition of the Options X conference for the Control of Influenza conference in Singapore. This conference is ISIRV's (International Society for Influenza and other Respiratory Virus Diseases) premier event and remains the largest international conference exclusively dedicated to Influenza prevention, control and treatment. Alexandre Le Vert, Chief Executive Officer and co-founder of Osivax, will present the interim safety and immunogenicity results from the first-in-human clinical trial on OVX836, Osivax universal flu vaccine candidate. Delphine Guyon-Gellin, Chief Business Development Officer, will co-present with Nicolas Noulin from hVIVO some analyses on the impact of pre-existing NP-specific T-cell immunity on symptom reduction in human challenge model. Two posters will also be presented on OVX836 preclinical results showing that OVX836 protect ferrets in flu challenge study and that OVX836 protection is mediated by CD8 T-cells as demonstrated in mice passive transfer studies.
https://2019.isirv.org/
IVW 2019 - Influenza Vaccines for the World
April 2-4, 2019
Edinburgh, Scotland
Osivax is proud to announce that its presentation has been selected to be presented at the Influenza Vaccines for the World (IVW) conference in Edinburgh on April 2-4th 2018. Alexandre Le Vert, Chief Executive Officer and co-founder of Osivax, will present preclinical efficacy data on OVX836, a multimerized nucleoprotein-based flu vaccine candidate, that protects mice against lethal challenge with multiple strains of influenza A viruses.
The IVW series is an international forum for world renowned experts in the field of influenza vaccines and related issues (adjuvant, delivery and vaccination strategies) to report on the latest data and trends associated with current and new influenza vaccines & technologies and their availability, delivery & implementation worldwide.
http://www.meetingsmanagement.co.uk/index.php?option=com_content&view=article&id=529&Itemid=947
Edinburgh, Scotland
Osivax is proud to announce that its presentation has been selected to be presented at the Influenza Vaccines for the World (IVW) conference in Edinburgh on April 2-4th 2018. Alexandre Le Vert, Chief Executive Officer and co-founder of Osivax, will present preclinical efficacy data on OVX836, a multimerized nucleoprotein-based flu vaccine candidate, that protects mice against lethal challenge with multiple strains of influenza A viruses.
The IVW series is an international forum for world renowned experts in the field of influenza vaccines and related issues (adjuvant, delivery and vaccination strategies) to report on the latest data and trends associated with current and new influenza vaccines & technologies and their availability, delivery & implementation worldwide.
http://www.meetingsmanagement.co.uk/index.php?option=com_content&view=article&id=529&Itemid=947
2018 World Influenza Conference
September 7-10, 2018
Beijing, China
Osivax is proud to announce that its poster has been selected to be presented at the World Influenza Conference in Beijing on September 7-10th 2018. Alexandre Le Vert, Chief Executive Officer and co-founder of Osivax, will present preclinical efficacy data on OVX836, a universal flu vaccine candidate, that protects mice against lethal challenge with multiple A-strain influenza viruses.
For the centenary of the 1918 influenza pandemic, the World Influenza Conference will examine our preparedness for the next pandemic and develop a path forward based on the lessons learned from past pandemics. The 3-day international congress offers the opportunity to Osivax to present its universal influenza vaccine candidate and get involved in dialogue between policy makers, public health officials, field workers, and industry.
http://www.apaci.asia/activities/apaci-meetings/world-influenza-conference-2018
Beijing, China
Osivax is proud to announce that its poster has been selected to be presented at the World Influenza Conference in Beijing on September 7-10th 2018. Alexandre Le Vert, Chief Executive Officer and co-founder of Osivax, will present preclinical efficacy data on OVX836, a universal flu vaccine candidate, that protects mice against lethal challenge with multiple A-strain influenza viruses.
For the centenary of the 1918 influenza pandemic, the World Influenza Conference will examine our preparedness for the next pandemic and develop a path forward based on the lessons learned from past pandemics. The 3-day international congress offers the opportunity to Osivax to present its universal influenza vaccine candidate and get involved in dialogue between policy makers, public health officials, field workers, and industry.
http://www.apaci.asia/activities/apaci-meetings/world-influenza-conference-2018
UIV 2018 - Universal Influenza Vaccines
April 16-18, 2018
Lausanne, Switzerland
Osivax is proud to announce that its Abstract has been selected for an Oral Presentation at Universal Influenza Vaccines congress in Lausanne on April 16-18th 2018. Dr Fergal Hill, Chief Scientific Officer and co-founder of Osivax, will present the immunogenicity profile of OVX836, a universal flu vaccine candidate eliciting powerful immune responses against the Influenza NucleoProtein in three different animal models. The UIV is an international annual forum for world renowned experts in the field of influenza vaccines and related issues (adjuvants, delivery, vaccination strategies) to report on the latest data and trends associated with current and new influenza vaccines.
http://www.meetingsmanagement.co.uk/index.php?option=com_content&view=article&id=456&Itemid=824
Lausanne, Switzerland
Osivax is proud to announce that its Abstract has been selected for an Oral Presentation at Universal Influenza Vaccines congress in Lausanne on April 16-18th 2018. Dr Fergal Hill, Chief Scientific Officer and co-founder of Osivax, will present the immunogenicity profile of OVX836, a universal flu vaccine candidate eliciting powerful immune responses against the Influenza NucleoProtein in three different animal models. The UIV is an international annual forum for world renowned experts in the field of influenza vaccines and related issues (adjuvants, delivery, vaccination strategies) to report on the latest data and trends associated with current and new influenza vaccines.
http://www.meetingsmanagement.co.uk/index.php?option=com_content&view=article&id=456&Itemid=824